Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

WST vs BRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BRO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 5–5 Matrix Metrics)

BRO Overall Winner 6-Pillar Tally: WST 0 – 6 BRO Matrix Metrics: WST 5 – 5 BRO

As of Nov 20, 2026, Brown & Brown, Inc. (BRO) is the stronger overall head-to-head candidate over West Pharmaceutical Services, Inc. (WST) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WST carries a Unified Composite Score of 33.2/100 (SELL) at $390.30 (37.5x Forward P/E, 22.9% operating margin), whereas BRO carries 44.0/100 (HOLD) at $73.07 (15.4x Forward P/E, 26.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WST vs BRO
WST NYSE
West Pharmaceutical Services, Inc.
Surgical & Medical Instruments & Apparatus
$390.30
-1.61% 1D
Market Cap $27.6B
TTM Revenue $3.40B
Forward P/E 37.5x
Beta / 30D Vol 0.46β · 27% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 35.0 Fund 33.0 Flow 54.0 Mom 1.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.2 · SMA20: $406.55 · SMA50: $386.53
BRO NYSE Head-to-Head Winner
Brown & Brown, Inc.
Insurance Agents, Brokers & Service
$73.07
+1.0% 1D
Market Cap $24.0B
TTM Revenue $6.81B
Forward P/E 15.4x
Beta / 30D Vol -0.48β · 38% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 44.0 Fund 49.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.3 · SMA20: $71.31 · SMA50: $67.38

6-Pillar Scorecard Institutional Category Breakdown (WST 0 – 6 BRO)

Columns: Metric · WST · BRO
1. Valuation Multiples BRO
Forward P/E 37.5x 15.4x
Trailing P/E 44.5x 23.0x
PEG Ratio 2.94x 1.88x
EV / Revenue 8.1x 4.5x
2. Growth & Scale BRO
Revenue Growth (YoY) +8.7% +9.7%
Earnings Growth (YoY) +57.3% -1.0%
TTM Revenue (USD) $3.40B $6.81B
Market Cap $27.6B $24.0B
3. Profitability & Quality BRO
Gross Margin 37.6% 49.8%
Operating Margin 22.9% 26.8%
Net Profit Margin 18.8% 17.9%
Return on Equity (ROE) 21.2% 9.8%
4. Balance Sheet & Cash Flow BRO
Cash Generation (TTM) $453M $1.49B
Cash Flow Margin 13.3% 21.8%
Net Cash / Leverage $159M Net Cash $6.94B Net Debt (0.64x D/E)
Dividend Yield 0.22% 0.91%
5. Options & Positioning BRO
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 28.2% (11th %ile) 30.8% (8th %ile)
Put/Call OI Skew N/A 0.08x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BRO
OpEx & R&D Intensity 14.7% of Rev ($499M) 23.0% of Rev ($1.57B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Instruments & Supplies Operator Insurance Brokers Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WST (5) vs BRO (5)
Institutional Metric WST BRO Criterion Row Edge
Market Capitalization
Scale
$27.6B $24.0B Larger Scale WST
Trailing P/E Ratio
Valuation
44.5x 23.0x Lower Multiple BRO
Forward P/E Ratio
Valuation
37.5x 15.4x Lower Multiple BRO
Revenue Growth (YoY)
Growth
+8.7% +9.7% Higher Growth BRO
Operating Margin (TTM)
Profitability
22.9% 26.8% Higher Margin BRO
Net Profit Margin
Profitability
18.8% 17.9% Higher Margin WST
Return on Equity (ROE)
Capital Efficiency
21.2% 9.8% Higher ROE WST
52-Week Range Position
Momentum
78% ($224–$438) 67% ($54–$83) Stronger Trend WST
Beta / 30D Volatility
Risk Regime
0.46β · 27% Vol -0.48β · 38% Vol Lower Realized Risk WST
Unified Institutional Score
Composite Signal
33.2 / 100 (SELL) 44.0 / 100 (HOLD) Higher Composite BRO
Trailing 12M Revenue (USD)
Operating Scale
$3.40B $6.81B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
37.6% 49.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.94x PEG · 8.1x EV/Rev 1.88x PEG · 4.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$453M ($159M Net Cash) $1.49B ($6.94B Net Debt (0.64x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon WST +0.96 pp
WST: -0.95% · BRO: -1.91%
3M Horizon WST +12.55 pp
WST: +10.47% · BRO: -2.08%
6M Horizon BRO +3.02 pp
WST: +23.35% · BRO: +26.37%
1Y Horizon WST +58.62 pp
WST: +51.34% · BRO: -7.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period WST Revenue BRO Revenue WST Op. Margin BRO Op. Margin Margin Leader
FY2018 $1.72B $2.01B 14.0% 17.1% BRO
FY2019 $1.84B $2.39B 16.1% 16.7% BRO
FY2020 $2.15B $2.61B 19.0% 18.4% WST
FY2021 $2.83B $3.05B 26.6% 19.2% WST
FY2022 $2.89B $3.57B 25.4% 18.8% WST
FY2023 $2.95B $4.26B 22.9% 20.5% WST
FY2024 $2.89B $4.80B 19.7% 20.7% BRO
FY2025 $3.07B $5.90B 19.0% 17.9% WST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.2%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BRO CONSOLIDATION
81d in phase · OBV NEUTRAL
Current IV 30.8%
IV Percentile 8th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $396.39 · IV 28.3%

WST Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($39,639)

Compare $39,639 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 28.3% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $410 / $420 Bull Call Spread

Buy 1x $410C · Sell 1x $420C · 29d

Net Entry $603 Debit
T+5d @ +5% Move +$152 (+25%)
Max Risk / Buffer $603 Capped
5d Edge & Liquidity 0.6x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $370 / $350 Bull Put Spread

Sell 1x $370P · Buy 1x $350P · 57d

Net Entry $163 Credit
Max Credit / Yield +$163 (+8.9% RoM)
Max Risk / Buffer -7.1% Cushion ($1,837 Mgn)
5d Edge & Liquidity 80% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WST Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $27.6B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment 14.7% of Rev ($499M)
90D Engineering Disclosures 0 Published
BRO Moat Profile Scale & Operating Efficiency Moat
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $24.0B market capitalization and 26.8% operating margin.
OpEx & R&D Reinvestment 23.0% of Rev ($1.57B)
90D Engineering Disclosures 0 Published

Investor FAQ WST vs BRO Key Questions & Quantitative Answers

As of Nov 20, 2026, Brown & Brown, Inc. (BRO) is the stronger overall head-to-head candidate over West Pharmaceutical Services, Inc. (WST) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). WST carries a Unified Composite Score of 33.2/100 (SELL) at $390.30 (37.5x Forward P/E, 22.9% operating margin), whereas BRO carries 44.0/100 (HOLD) at $73.07 (15.4x Forward P/E, 26.8% operating margin). Technically, WST sits in a Neutral phase (RSI 43.2, UNCLASSIFIED options structure) and BRO sits in a Neutral phase (RSI 57.3, CONSOLIDATION options structure).

BRO leads the Growth & Scale pillar: WST posts +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin), compared with BRO at +9.7% YoY revenue growth and -1.0% YoY earnings growth on $6.81B TTM revenue (49.8% gross margin, 26.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), WST cumulative revenue shifted +78.5% while BRO shifted +193.5%. In operating R&D and SG&A reinvestment, WST deploys 14.7% of Rev ($499M) (0 90-day corporate R&D disclosures) versus 23.0% of Rev ($1.57B) (0 disclosures) for BRO.

BRO screens cheaper on headline valuation multiples. WST trades at 37.5x Forward P/E, 44.5x Trailing P/E, 2.94x PEG, and 8.1x EV/Revenue (13.3% FCF margin), whereas BRO trades at 15.4x Forward P/E, 23.0x Trailing P/E, 1.88x PEG, and 4.5x EV/Revenue (21.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WST (21.2% ROE) versus BRO (9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, WST carries 28.2% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 27% Vol realized risk). By comparison, BRO carries 30.8% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.48β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.